Bristol-Myers Squibb Co (BMY) was Reiterated by Deutsche Bank to “Hold” while Lowering the Price Target of the company shares to $ 62 from a previous price target of $68 . Deutsche Bank advised their investors in a research report released on Aug 8, 2016.
Many Wall Street Analysts have commented on Bristol-Myers Squibb Co. Credit Suisse Downgraded Bristol-Myers Squibb Co on Aug 8, 2016 to ” Neutral”, Price Target of the shares are set at $63.Bristol-Myers Squibb Co was Downgraded by Morgan Stanley to ” Equal-Weight” on Aug 5, 2016. Bristol-Myers Squibb Co was Initiated by Hilliard Lyons to “Neutral” on May 23, 2016.
On the company’s financial health, Bristol-Myers Squibb Co reported $0.69 EPS for the quarter, beating the analyst consensus estimate by $ 0.03 according to the earnings call on Jul 28, 2016. Analyst had a consensus of $0.66. The company had revenue of $4881.00 million for the quarter, compared to analysts expectations of $4657.63 million. The company’s revenue was up 17.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.53 EPS.
Bristol-Myers Squibb Co closed down -12.04 points or -15.99% at $63.28 with 8,62,12,615 shares getting traded on Friday. Post opening the session at $62, the shares hit an intraday low of $61.56 and an intraday high of $64.77 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
In a different news, on Jul 11, 2016, Lamberto Andreotti (director) sold 23,200 shares at $74.65 per share price. According to the SEC, on Jun 16, 2016, John E Elicker (SVP, Public Affairs & IR) sold 11,820 shares at $72.69 per share price. On May 24, 2016, Charles A Bancroft (EVP & Chief Financial Officer) sold 30,201 shares at $70.79 per share price, according to the Form-4 filing with the securities and exchange commission.
Bristol-Myers Squibb Company (BMS) is engaged in the discovery development licensing manufacturing marketing distribution and sale of biopharmaceutical products across the world. The Company’s products are sold to wholesalers retail pharmacies hospitals government entities and the medical profession. The Company manufactures its products in the United States Puerto Rico and in six foreign countries. The Company promotes the use of its products directly to healthcare professionals and providers such as doctors nurse practitioners physician assistants pharmacists technologists hospitals Pharmacy Benefit Managers (PBMs) and Managed Care Organizations (MCOs). It also provides information about the use of its products to consumers in the United States through direct-to-consumer print radio television and digital advertising and promotion. In addition the Company holds rights to F001287 which is a preclinical small-molecule IDO1-inhibitor.